EmailBiogen (BIIB 343.20, +44.39) has spiked 14.9% in premarket after
the company's Phase II study of an anti-amyloid beta protofibril antibody
showed positive results in patients with early Alzheimer's disease. Today's
pre-market gain has lifted Biogen to levels not seen since early February.
Biogen's Study 201 is being conducted in collaboration with
Japan's Eisai. Shares of Eisai spiked 19.5% in Tokyo overnight.
Last evening, the two companies announced that Study 201, a study of 856 patients with mild cognitive
impairment due to Alzheimer's disease or mild Alzheimer's dementia, achieved statistical
significance on key endpoints at 18 months. The study showed slowing
progression in Alzheimer's Disease Composite Score and a reduction of amyloid
accumulated in the brain, measured with a PET scan.
The drug candidate showed acceptable tolerability profile through
18 months of administration with infusion-related reactions representing the
most common side effect. These reactions were mostly mild to moderate in
severity. The two companies will present detailed results of the study at
future academic conferences.
Eisai's Chief Clinical Officer and Chief Medical Officer of the
company's Neurology Business Group, Lynn Kramer, M.D., commented on the
results, saying "This is the first late-stage anti-amyloid antibody study
to successfully achieve statistically significant results at 18 months, further
validating the amyloid hypothesis."
than one year.
The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.
Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for
use by individuals, as long as the feeds are used for such individual’s
personal, non-commercial use. Any other uses, including without
limitation the incorporation of advertising into or the placement
of advertising associated with or targeted towards the RSS Content,
are strictly prohibited. You are required to use the RSS feeds
as provided by Briefing.com and you may not edit or modify the
text, content or links supplied by Briefing.com. To acquire
more extensive licensing rights to Briefing.com content please
review this page.
Link to Content Pages:
The RSS service may be used only with those platforms from which
a functional link is made available that, when accessed, takes
the viewer directly to the display of the full article on the
Briefing.com web site. You may not display the RSS content in
a manner that does not permit successful linking to, redirection
to or delivery of the applicable Briefing.com web site page.
You may not insert any intermediate page, “splash” page or any
other content between the RSS link and the applicable Briefing.com
web site page.
Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS
content, and any and all Briefing.com logos and trademarks used
in connection with the RSS service. You are required to provide
appropriate attribution to the Briefing.com web site in connection
with your use of the RSS feeds. If you provide this attribution
using a graphic we require you to use the Briefing.com web site
logo that we have incorporated into the Briefing.com RSS feed.
Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any
or all of the RSS feeds at any time and to require you to cease
displaying, distributing or otherwise using any or all of the
RSS feeds for any reason including, without limitation, your
violation of any provision of these Terms of Use or the terms
and conditions of the Briefing.com Reader Agreement. Briefing.com
assumes no liability for any of your activities in connection
with the RSS feeds or for your use of the RSS feeds in connection
with your web site.
